Ticker > Company >

Sandu Pharmaceutical share price

Sandu Pharmaceuticals Ltd.

BSE: 524703 SECTOR: Pharmaceuticals & Drugs  10k   22   0

50.37
0 0
BSE: 25 Apr 04:01 PM

Price Summary

Today's High

₹ 53.1

Today's Low

₹ 50.25

52 Week High

₹ 69.2

52 Week Low

₹ 43.75

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

48.66 Cr.

Enterprise Value

47.46 Cr.

No. of Shares

0.97 Cr.

P/E

26.81

P/B

1.18

Face Value

₹ 10

Div. Yield

1.59 %

Book Value (TTM)

₹  42.86

CASH

1.2 Cr.

DEBT

0 Cr.

Promoter Holding

42.9 %

EPS (TTM)

₹  1.88

Sales Growth

2.96%

ROE

3.66 %

ROCE

5.35%

Profit Growth

-4.15 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year2.96%
3 Year4.62%
5 Year6.36%

Profit Growth

1 Year-4.15%
3 Year10.16%
5 Year16.9%

ROE%

1 Year3.66%
3 Year4.85%
5 Year4.65%

ROCE %

1 Year5.35%
3 Year7.2%
5 Year7.05%

Debt/Equity

0

Price to Cash Flow

63.91

Interest Cover Ratio

33.8937

CFO/PAT (5 Yr. Avg.)

2.46196435723087

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 42.90 0.00
Dec 2024 42.90 0.00
Sep 2024 42.90 0.00
Jun 2024 42.90 0.00
Mar 2024 42.90 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 33.8937.
  • The company has an efficient Cash Conversion Cycle of 27.7386 days.
  • Company has a healthy liquidity position with current ratio of 2.0955.
  • The company has a good cash flow management; CFO/PAT stands at 2.46196435723087.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 7.74420390681723.

 Limitations

  • The company has shown a poor revenue growth of 4.61977832711657% for the Past 3 years.
  • Company has a poor ROE of 4.84884819143897% over the past 3 years.
  • The company has a low EBITDA margin of 3.57871440488845% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Net Sales 17.43 15.6 17.05 17.71 18.37
Total Expenditure 16.92 14.99 16.64 16.79 17.38
Operating Profit 0.51 0.6 0.41 0.92 0.99
Other Income 0.03 0.31 0.05 0.03 0.03
Interest 0.02 0.01 0.02 0.03 0.03
Depreciation 0.14 0.19 0.16 0.17 0.19
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.38 0.72 0.27 0.74 0.8
Tax 0.17 0.12 0.1 0.24 0.24
Profit After Tax 0.21 0.59 0.17 0.5 0.56
Adjusted EPS (Rs) 0.21 0.61 0.17 0.52 0.57

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 48.45 58.76 65.5 65.35 67.28
Total Expenditure 46.91 56.6 62.63 62.86 64.98
Operating Profit 1.53 2.16 2.87 2.49 2.3
Other Income 0.38 0.19 0.08 0.33 0.42
Interest 0.43 0.12 0.11 0.08 0.06
Depreciation 0.55 0.56 0.53 0.52 0.58
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.92 1.68 2.32 2.22 2.07
Tax 0.2 0.59 0.73 0.7 0.61
Net Profit 0.72 1.09 1.59 1.52 1.46
Adjusted EPS (Rs.) 1.02 1.38 1.8 1.58 1.51

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 7.08 7.92 8.81 9.66 9.66
Total Reserves 22.16 25.57 27.66 29.58 30.93
Borrowings 0 0 0 0 0
Other N/C liabilities 0.85 0.95 0.94 1.04 1.18
Current liabilities 11.33 12.52 11.87 13.88 10.64
Total Liabilities 41.41 46.96 49.28 54.17 52.42
Assets
Net Block 16.6 16.17 16 16.62 17.88
Capital WIP 0 0 0.48 0.42 0
Intangible WIP 0 0 0 0 0
Investments 0.82 0.24 9.11 9.66 10.43
Loans & Advances 1.32 0 0 0 0
Other N/C Assets 0.25 0 0.05 1.94 1.82
Current Assets 22.42 30.54 23.65 25.54 22.3
Total Assets 41.41 46.96 49.28 54.17 52.42
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 0.92 1.68 2.32 2.22 2.07
Adjustment 0.96 0.62 0.63 0.48 0.41
Changes in Assets & Liabilities 4.47 5.75 -1.13 -1.78 -1.22
Tax Paid -0.14 -0.46 -0.88 -0.7 -0.5
Operating Cash Flow 6.2 7.59 0.95 0.22 0.76
Investing Cash Flow -0.37 -5.58 -5.47 0.53 -1.31
Financing Cash Flow -5.36 1.3 0.93 0.58 -0.72
Net Cash Flow 0.48 3.31 -3.59 1.33 -1.27

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 42.90 42.90 42.90 42.90 42.90
akshath finvest and prope... 5.12 5.12 5.12 5.12 5.12
geeta u sandu 0.88 0.88 0.88 0.88 0.88
jayshree bhaskar sandu 7.63 7.63 7.63 7.63 7.63
minal shashank sandu 0.63 0.63 0.63 0.63 0.63
shashank bhaskar sandu 14.17 14.17 14.17 14.17 14.17
shubhada prabhakar sandu 0.10 0.10 0.10 0.10 0.10
umesh bhaskar sandu 14.37 14.37 14.37 14.37 14.37
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 57.10 57.10 57.10 57.10 57.10
hitesh kuvelkar 1.26 1.26 1.26 1.26 1.26
llp 0.32 0.34 0.35 0.38 0.23
neelamber leasing and fin... 4.71 4.71 4.71 4.71 4.71
noumura realty and constr... 2.27 2.27 2.27 2.27 2.27
phybrichem engineers priv... 1.61 1.61 1.61 1.61 1.61
sanbro marketing services... 2.59 2.59 2.59 2.59 2.59
sanmark realty and financ... 5.63 5.63 5.63 5.63 5.63
tanvi jignesh mehta 2.57 2.41 2.54 2.42 3.29
trans scan securities pri... 1.10 1.04 - - -
yogish shetty 1.10 1.07 - - -

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Sandu Pharmaceuticals informs about disclosure 21 Apr, 9:53 AM Sandu Pharmaceuticals informs about clarification 19 Feb, 5:16 PM Sandu Pharmaceuticals informs about newspaper cutting 15 Feb, 2:25 PM Sandu Pharmaceutical - Quaterly Results 13 Feb, 5:33 PM Sandu Pharmaceutical - Quaterly Results 13 Feb, 5:33 PM Sandu Pharmaceuticals informs about disclosure 21 Jan, 5:22 PM Sandu Pharmaceuticals informs about certificate 9 Jan, 12:56 PM Sandu Pharmaceuticals informs about closure of trading window 21 Dec, 3:18 PM Sandu Pharmaceuticals informs about stop transfer receipt 18 Dec, 1:08 PM Sandu Pharmaceuticals informs about issuance of duplicate share certificate 2 Dec, 4:00 PM Sandu Pharmaceuticals informs about closure of trading window 23 Sep, 12:16 PM Sandu Pharmaceuticals informs about stop transfer request 21 Sep, 10:28 AM Sandu Pharmaceuticals informs about stop transfer request 21 Aug, 3:18 PM Sandu Pharmaceutical - Quaterly Results 12 Aug, 7:36 PM Sandu Pharmaceutical - Quaterly Results 12 Aug, 7:36 PM Sandu Pharmaceuticals informs about details of loss of certificate 8 Aug, 2:29 PM Sandu Pharmaceuticals informs about board meeting 3 Aug, 2:28 PM Sandu Pharmaceuticals informs about stop transfer request 20 Jun, 1:01 PM Sandu Pharmaceutical - Quaterly Results 5 Jun, 7:22 PM Sandu Pharmaceutical - Quaterly Results 5 Jun, 7:22 PM Sandu Pharmaceuticals informs about loss of share certificate 14 May, 2:12 PM Sandu pharmaceuticals informs about details of loss of certificate 4 May, 11:24 AM Sandu Pharmaceuticals informs about stop transfer receipt 30 Apr, 12:44 PM Sandu Pharmaceuticals informs about details of loss of certificate 16 Apr, 4:58 PM Sandu Pharmaceuticals informs about compliance certificate 11 Apr, 1:36 PM Sandu Pharmaceuticals informs about stop transfer request 30 Mar, 11:10 AM Sandu Pharmaceuticals informs about details of loss of certificate 20 Mar, 1:01 PM Sandu Pharmaceuticals informs about details of loss of certificate 8 Mar, 12:24 PM Sandu Pharmaceutical - Quaterly Results 14 Feb, 9:04 PM Sandu Pharmaceuticals informs about issuance of duplicate share certificate 20 Jan, 12:30 PM Sandu Pharmaceuticals informs about resignation of CFO 22 Nov, 5:12 PM Sandu Pharmaceuticals informs about details of loss of certificate 18 Nov, 10:59 AM Sandu Pharmaceuticals informs about stop transfer request 21 Oct, 11:06 AM Sandu Pharmaceuticals informs about issuance of duplicate share certificate 25 Sep, 10:50 AM Sandu Pharmaceuticals informs about issuance of duplicate shares certificate 6 Sep, 12:28 PM Sandu Pharmaceuticals informs about stop transfer intimation 11 Aug, 11:55 AM Sandu Pharmaceuticals informs about issuance of duplicate share certificate 29 Jul, 10:17 AM Sandu Pharmaceuticals informs about loss of share certificates 21 Jul, 12:15 PM Sandu Pharmaceuticals informs about loss of share certificate 15 Jul, 10:29 AM Sandu Pharmaceuticals informs about loss of share certificate 1 Jul, 12:27 PM Sandu Pharmaceuticals informs about loss of share certificate 15 Jun, 2:30 PM Sandu Pharmaceuticals informs about issuance of duplicate share certificate 9 May, 12:29 PM Sandu Pharmaceuticals informs about closure of trading window 23 Mar, 12:23 PM Sandu Pharmaceuticals informs about details of loss of certificate 18 Mar, 3:45 PM Sandu Pharmaceuticals informs about stop transfer request 14 Mar, 12:42 PM Sandu Pharmaceuticals informs about disclosure 25 Feb, 2:25 PM Sandu Pharmaceuticals informs about issuance of duplicate share certificate 20 Feb, 3:18 PM Sandu Pharmaceuticals informs about newspaper cutting 16 Feb, 4:45 PM Sandu Pharmaceuticals informs about stop transfer request 6 Feb, 10:36 AM Sandu Pharmaceuticals informs about loss of share certificate 27 Jan, 11:46 AM

Sandu Pharmaceutical Stock Price Analysis and Quick Research Report. Is Sandu Pharmaceutical an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Sandu Pharmaceutical and its performance over the period of time. Sandu Pharmaceutical stock price today is Rs 50.37.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Sandu Pharmaceutical cash from the operating activity was Rs 0.7614 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Sandu Pharmaceutical has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Sandu Pharmaceutical , the EPS growth was -4.1524 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Sandu Pharmaceutical has OPM of 3.41450074092569 % which is a bad sign for profitability.
     
  • ROE: Sandu Pharmaceutical have a poor ROE of 3.6588 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Sandu Pharmaceutical is Rs 50.37. One can use valuation calculators of ticker to know if Sandu Pharmaceutical share price is undervalued or overvalued.
Last Updated on:
Brief about Sandu Pharmaceutical
X